All analyses
AI analysis

Arpico Insurance Plc: research report

Fairly valuedbearishNov 13, 2026

Evidence points bearish because audited annual profit fell 96.6% and the shares trade at 207 times earnings. The price remains below book value.

Reports without a focus are public, one per stock per day. Generation usually takes about 15 minutes, and we'll notify you when it's ready.

Why bearish

  • Audited 2025 net profit fell 96.6%, leaving a very small earnings base behind the current valuation.
  • September revenue fell 16.5% year-on-year and the quarter remained loss-making, despite the loss narrowing to LKR 0.8 million.

Against this. The shares trade at 0.96 times book value, below the insurance-sector median of 1.51 times.

Net margin
-0.2%sector 1.4%
from -2.1% a year earlier, revenue -16.5%
Return on equity
0.5%sector 7.2%
full year to Dec 31, 2025
P/E
210.0sector 15.6
earnings Rs 0.12 per share, year to Dec 2025
P/B
0.98sector 1.46
book Rs 25.82 per share

Current figures, updated daily from filings to Sep 30, 2026. The report below was written on Nov 13, 2026. Sector figures are the median of 11 listed companies in the same sector.

Overview

Arpico Insurance is a Sri Lankan life and health insurer, serving individual and corporate customers through its distribution network and digital service infrastructure. The central change is a sharply weakened earnings base: the latest audited year almost eliminated profit, and the September quarter remained loss-making even though the loss was smaller than a year earlier.

Price performance

The share closed at LKR 24.80 on 13 November 2026 after falling 35.1% over one year, against a 4.7% fall in the ASPI. It sat 13.5% up its 52-week range, placing it close to the year's low rather than near its peak.

The three-year record includes several substantial retreats, with the deepest reaching 42% and not yet recovering. Liquidity is exceptionally limited: a LKR 1 million order is more than everything that trades on a typical day (10496% of it), making that size a very large part of normal trading.

Valuation

The valuation is split between book value and earnings. At 207 times P/E, the market price represents 207 rupees for every rupee of trailing profit, and is the highest P/E among the nine insurance peers with usable earnings multiples. That multiple reflects a trailing EPS base of only LKR 0.12, so the valuation rests on very little reported profit.

P/B is more restrained at 0.96 times, meaning the shares cost 96 cents for each rupee of net assets, versus the sector median of 1.51 times. It ranks in the cheaper fifth of the sector on P/B and is "cheaper than 50% of days since March 2015". The latest audited return on equity was only 0.5%, however, so the below-book valuation is consistent with weak earnings on those assets. No dividend is on record in the last two years.

News and sentiment

There were no material company articles in the latest 90-day news window. Earlier reports in June and July covered the 2025 profit disclosure and routine Board and audit committee appointments, without disclosing a new earnings-sized operating development.

Financials

September-quarter revenue fell 16.5% year-on-year to LKR 416.9 million, while the net loss narrowed by LKR 9.5 million to LKR 0.8 million. Gross margin is unavailable for both September comparisons, and operating margin is unavailable for September 2026, preventing a like-for-like operating-margin assessment. Net margin improved to -0.2% from -2.0% a year earlier: the insurer still lost money, but only around a fifth of a cent on each rupee of revenue rather than two cents.

That net margin was middling among the company's eight September quarters on record, ranking sixth. The result therefore narrowed a loss but did not establish a strong quarter against its own comparable September history.

The latest audited year ended December 2025 was much weaker, with net profit down 96.6% and return on equity at 0.5%. Equity at September was LKR 1.7 billion, down from LKR 2.0 billion a year earlier, while the ordinary share count remained 66.2 million; the weaker per-share outcome is therefore not the mechanical result of a share-count increase.

Risks

The main financial risk is the insurer's higher balance-sheet leverage. Total liabilities were 2.22 times equity at the latest audited year, up from 1.72 times a year earlier, meaning the company had LKR 2.22 of obligations, including insurance liabilities, for each rupee of equity supporting them.

The earnings risk is equally material: audited profit fell 96.6%, and the latest quarter still made a loss. For an insurer, falling bond yields can affect investment portfolio valuations and reinvestment income; this is sector context as at 13 November 2026, not evidence of a company-specific effect. The very thin share turnover is a separate practical risk for building or exiting a position.

Outlook

As at 13 November 2026, the next material event is the audited year-end filing for 31 December 2026, expected between 28 April and 3 June 2027. It will show whether the weak 2025 earnings base and September loss persisted or whether underwriting and investment income restored profitability.

The available data cannot separate the causes of the revenue contraction or quantify the contribution from the insurer's investment portfolio. Until the annual filing, the reported record supports a narrowed quarterly loss, but not a demonstrated earnings recovery.

About this report. Generated on Nov 13, 2026 from market data up to Nov 13, 2026, 0 material news articles over 90 days and financials to Sep 30, 2026, and scored 43 of 100 on value (fairly valued) when it was written. Every figure is drawn from EquityLK's own data on this company. AI research can contain errors, so treat it as a starting point, not investment advice.

Previous reports